Serum APE1 Autoantibodies: A Novel Potential Tumor Marker and Predictor of Chemotherapeutic Efficacy in Non-Small Cell Lung Cancer

Abstract

Apurinic/apyrimidinic endonuclease 1 (APE1), which has the dual functions of both DNA repair and redox activity, has been reported to be highly expressed in non-small cell lung cancer (NSCLC), and this appears to be a characteristic related to chemotherapy resistance. In this study, we identified serum APE1 autoantibodies (APE1-AAbs) in NSCLC patients and healthy controls by immunoblotting and investigated the expression of APE1-AAbs by indirect ELISA from the serum of 292 NSCLC patients and 300 healthy controls. In addition, serum APE1-AAbs level alterations of 91 patients were monitored before and after chemotherapy. Our results showed that serum APE1-AAbs can be detected in both NSCLC patients and healthy controls. Serum APE1-AAbs were significantly higher than those of healthy controls and closely related to APE1 antigen levels both in tumor tissues and the peripheral blood. Moreover, the change in levels of serum APE1-AAbs in NSCLC is closely associated with the response to chemotherapy. These results suggest that APE1-AAbs is a potential tumor marker and predictor of therapeutic efficacy in NSCLC.

Human Apurinic/Apyrimidinic Endonuclease 1

“…Moreover, in an effort to reduce experimental variability from lab to lab, as well as any artifacts, standardized methods for sample preparation and handling, and for immunodetection (e.g., immunohistochemistry) that , and hopefully will help provide a more definitive understanding of the molecular roles of APE1 in the carcinogenic process. Finally, it is noteworthy that elevated serum auto-antibodies against APE1 have recently been associated with the auto-immune disease, systemic lupus erythematosus, particularly those patients with psychiatric manifestations, and non-small cell lung carcinoma (33,98). Future investigations will need to determine the contribution, if any, of the APE1 auto-antibodies to disease etiology and, more generally, whether APE1 autoantibodies have utility in basic serological examinations.…”

Salivary Auto-Antibodies as Noninvasive Diagnostic Markers of Oral Cavity Squamous Cell Carcinoma

“…Auto-Abs are highly specific, stable, and handily detectable in small volumes of specimens with well-established secondary reagents. These advantages lead many efforts into discovery of auto-Abs as biomarkers for detection of various types of cancers, such as colorectal (10)(11)(12), breast (13)(14)(15), ovarian (16,17), lung (18)(19)(20), liver (21,22), and pancreatic (23,24) cancers. As for OSCC, five auto-Abs have been individually identified as serum biomarker candidates, including anti-p53 (25)(26)(27)(28), anti-survivin (29,30), anticytokeratin 8 (CK-8; ref.…”

Ultrasensitive Apurinic/Apyrimidinic Endonuclease 1 Immunosensing Based on Self-Enhanced Electrochemiluminescence of a Ru(II) Complex

“…1 Additionally, researches indicate that it has multiple possible roles in the response of human cancer to radiotherapy and chemotherapy. 2 Up to now, various methods and strategies have been applied for the detection of APE-1, such as enzyme-linked immunoassay (ELISA), 3 stopped-flow fluorescence analysis, 4 and electrophoretic mobility-shift assay (EMSA). 5 However, improvements are still required, as these methods remain cumbersome, time-consuming, and harmful to the operator's health.…”

“…17 In our previous work, we have prepared the apoferritin-templated poly(ethylenimine) (PEI) nanoparticles as labels based on in situ releasing the coreactant of PEI to develop a sensitive ECL immunosensor. 18 Subsequently, we also have constructed of a reagentless ECL immunosensor by immobilizing the coreactant of poly-L-lysine to enhance the ECL of Ru(bpy) 3 2+ for signal amplification. 19 Although the luminous intensity of the Ru(bpy) 3 2+ is indeed enhanced by adding additives as effective coreactant, it suffers from the problems of operational complexity, which would result in the adding the coreactant in the detection solution or immobilizing the coreactant on the sensing interface.…”